Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Prostatic Neoplasms 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Lung Neoplasms 2Liver Neoplasms 2Hemangiosarcoma 2Glioma 2Choriocarcinoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Trophoblastic Tumor, Placental Site 1Sarcoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1Disease Progression 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Astrocytoma 1Adult Solid Tumor 1Adenoma, Liver Cell 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × carotuximab × Clear all
NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

University of Alabama at Birmingham

Phase 1/2 Completed
15 enrolled 18 charts
Breast

Breast Neoplasms

NCT01326481 2019-03-18

TRC105

Tracon Pharmaceuticals Inc.

Phase 1/2 Completed
19 enrolled 9 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡